Literature DB >> 24130191

para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.

Teemu Haikarainen1, Jarkko Koivunen, Mohit Narwal, Harikanth Venkannagari, Ezeogo Obaji, Päivi Joensuu, Taina Pihlajaniemi, Lari Lehtiö.   

Abstract

Human tankyrases are attractive drug targets, especially for the treatment of cancer. We identified a set of highly potent tankyrase inhibitors based on a 2-phenyl-3,4-dihydroquinazolin-4-one scaffold. Substitutions at the para position of the scaffold's phenyl group were evaluated as a strategy to increase potency and improve selectivity. The best compounds displayed single-digit nanomolar potencies, and profiling against several human diphtheria-toxin-like ADP-ribosyltransferases revealed that a subset of these compounds are highly selective tankyrase inhibitors. The compounds also effectively inhibit Wnt signaling in HEK293 cells. The binding mode of all inhibitors was studied by protein X-ray crystallography. This allowed us to establish a structural basis for the development of highly potent and selective tankyrase inhibitors based on the 2-phenyl-3,4-dihydroquinazolin-4-one scaffold and outline a rational approach to the modification of other inhibitor scaffolds that bind to the nicotinamide site of the catalytic domain.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Wnt signaling; inhibitors; structural biology; structure-activity relationships; tankyrase

Mesh:

Substances:

Year:  2013        PMID: 24130191     DOI: 10.1002/cmdc.201300337

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  8 in total

Review 1.  Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.

Authors:  Shilong Zheng; Jiawang Liu; Yanyuan Wu; Tien L Huang; Guangdi Wang
Journal:  Future Med Chem       Date:  2015-12-16       Impact factor: 3.808

2.  Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.

Authors:  Jeffrey W Johannes; Lynsie Almeida; Bernard Barlaam; P Ann Boriack-Sjodin; Robert Casella; Rosemary A Croft; Allan P Dishington; Lakshmaiah Gingipalli; Chungang Gu; Janet L Hawkins; Jane L Holmes; Tina Howard; Jian Huang; Stephanos Ioannidis; Steven Kazmirski; Michelle L Lamb; Thomas M McGuire; Jane E Moore; Derek Ogg; Anil Patel; Kurt G Pike; Timothy Pontz; Graeme R Robb; Nancy Su; Haiyun Wang; Xiaoyun Wu; Hai-Jun Zhang; Yue Zhang; Xiaolan Zheng; Tao Wang
Journal:  ACS Med Chem Lett       Date:  2015-01-13       Impact factor: 4.345

3.  Scaffold hopping approach on the route to selective tankyrase inhibitors.

Authors:  Paride Liscio; Andrea Carotti; Stefania Asciutti; Martina Ferri; Maira M Pires; Sara Valloscuro; Jacob Ziff; Neil R Clark; Antonio Macchiarulo; Stuart A Aaronson; Roberto Pellicciari; Emidio Camaioni
Journal:  Eur J Med Chem       Date:  2014-10-05       Impact factor: 6.514

4.  Characterization of the DNA dependent activation of human ARTD2/PARP2.

Authors:  Ezeogo Obaji; Teemu Haikarainen; Lari Lehtiö
Journal:  Sci Rep       Date:  2016-10-06       Impact factor: 4.379

5.  Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation.

Authors:  Amit Bhardwaj; Yanling Yang; Beatrix Ueberheide; Susan Smith
Journal:  Nat Commun       Date:  2017-12-20       Impact factor: 14.919

6.  First body of evidence suggesting a role of a tankyrase-binding motif (TBM) of vinculin (VCL) in epithelial cells.

Authors:  Salomé Vilchez Larrea; Wanda Mariela Valsecchi; Silvia H Fernández Villamil; Laura I Lafon Hughes
Journal:  PeerJ       Date:  2021-05-27       Impact factor: 2.984

Review 7.  Tankyrases: structure, function and therapeutic implications in cancer.

Authors:  Teemu Haikarainen; Stefan Krauss; Lari Lehtio
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.

Authors:  Yves Nkizinkiko; Jenny Desantis; Jarkko Koivunen; Teemu Haikarainen; Sudarshan Murthy; Luca Sancineto; Serena Massari; Federica Ianni; Ezeogo Obaji; Maria I Loza; Taina Pihlajaniemi; Jose Brea; Oriana Tabarrini; Lari Lehtiö
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.